Enlivex Therapeutics Ltd. (NASDAQ:ENLV) Sees Significant Drop in Short Interest

Enlivex Therapeutics Ltd. (NASDAQ:ENLV) was the recipient of a large decline in short interest in December. As of December 15th, there was short interest totaling 233,417 shares, a decline of 79.7% from the November 30th total of 1,147,847 shares. Based on an average daily volume of 1,100,765 shares, the short-interest ratio is presently 0.2 days. Approximately 1.1% of the company’s shares are sold short. Approximately 1.1% of the company’s shares are sold short. Based on an average daily volume of 1,100,765 shares, the short-interest ratio is presently 0.2 days.

Enlivex Therapeutics Price Performance

Shares of NASDAQ ENLV traded down $0.03 during trading hours on Friday, hitting $0.75. 408,482 shares of the stock were exchanged, compared to its average volume of 905,682. The firm has a market capitalization of $18.16 million, a P/E ratio of -1.36 and a beta of 1.49. Enlivex Therapeutics has a one year low of $0.73 and a one year high of $2.10. The company’s 50 day moving average is $0.98 and its 200 day moving average is $1.10.

Enlivex Therapeutics (NASDAQ:ENLV) last issued its quarterly earnings results on Friday, November 14th. The company reported ($0.09) EPS for the quarter, topping the consensus estimate of ($0.12) by $0.03. Research analysts anticipate that Enlivex Therapeutics will post -0.7 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Enlivex Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Susquehanna International Group LLP bought a new stake in Enlivex Therapeutics in the third quarter valued at about $57,000. Jane Street Group LLC lifted its stake in Enlivex Therapeutics by 527.4% during the first quarter. Jane Street Group LLC now owns 80,759 shares of the company’s stock worth $78,000 after purchasing an additional 67,886 shares during the period. Finally, Citizens Financial Group Inc. RI acquired a new stake in Enlivex Therapeutics during the third quarter valued at approximately $241,000. 1.02% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of equities research analysts have commented on ENLV shares. HC Wainwright reiterated a “buy” rating and issued a $7.00 target price on shares of Enlivex Therapeutics in a research report on Tuesday, September 2nd. Weiss Ratings reiterated a “sell (d-)” rating on shares of Enlivex Therapeutics in a report on Monday. Wall Street Zen cut Enlivex Therapeutics to a “strong sell” rating in a research report on Saturday. D. Boral Capital reaffirmed a “hold” rating on shares of Enlivex Therapeutics in a research report on Monday, November 24th. Finally, D Boral Capital downgraded Enlivex Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Monday, November 24th. One research analyst has rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company has an average rating of “Hold” and an average target price of $10.00.

Enlivex Therapeutics Company Profile

Enlivex Therapeutics is a clinical-stage biopharmaceutical company headquartered in Ness Ziona, Israel, that focuses on developing innovative immunotherapies for life-threatening inflammatory conditions. Founded in 2015, the company trades on the NASDAQ under the symbol ENLV and leverages a proprietary cell-based platform to restore immune balance in critical care settings.

The company’s lead product candidate, Allocetra, comprises reprogrammed apoptotic cell therapy designed to recalibrate the innate immune system.